ABVC BioPharma, Inc. (ABVC) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin 100.0%, operating margin 9.2%, net margin 9.9%.
At the current price of $1.08, ABVC has negative trailing earnings (P/E not meaningful) and an ROE of -71.17%. Market capitalisation stands at $28M.
Balance sheet quality for ABVC: current ratio of 0.4, net debt of $2.7M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.08 |
| Market Cap | $28M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.18 |
| EV / EBITDA | -7.04 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -71.17% |
| Return on Invested Capital | -42.64% |
| Return on Assets | -37.55% |
| Gross Margin | 100.00% |
| Operating Margin | 918.55% |
| Net Margin | 992.85% |
Financial Health
| Debt / Equity | 0.17 |
| Current Ratio | 0.07 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.61 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ABVC | ABVC BioPharma, Inc. | $28M | 3.18 | -71.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | +24.70% |
| 3 months | -20.00% |
| Year-to-date | -49.30% |
| 1 year | -62.24% |
| 3 years | +1.89% |
| 5 years | -96.22% |
52-Week Range
| 52-week High | $3.40 |
| 52-week Low | $0.71 |
| Avg Volume (90d) | 135K |
Related companies: ATNM · FGEN · GRCE · JUNS · LTRN · LVTX · PDSB
Explore sector: Healthcare · Biotechnology
More sections of ABVC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks